NCT05882734 2026-02-17Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)EMD SeronoPhase 1/2 Active not recruiting61 enrolled
NCT05054725 2026-01-06Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesRevolution Medicines, Inc.Phase 2 Completed47 enrolled 17 charts
NCT04774952 2025-04-15Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Completed58 enrolled